Worth reading
38Recurring
Scored from 3 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
365600
sharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Extinguishment due to waiver of stock acquisition rights
発行・処分する株式数
Series 7: 194 rights extinguished (77,600 shares), 78 rights remaining after extinguishment (31,200 shares) / Series 10: 720 rights extinguished (288,000 shares), 130 rights remaining after extinguishment (52,000 shares)
Intended allottee
The Company's directors, employees and external collaborators
Terms of the stock acquisition rights
Exercise price
Series 7: ¥814 / Series 10: ¥1,050. Adjustment provision: Not disclosed
Exercise period
Series 7: 5 January 2020 to 15 December 2027 / Series 10: 1 October 2019 to 29 September 2029
Number of Stock Acquisition Rights
Series 7: 489 rights issued, 272 rights outstanding and unexercised, 194 rights extinguished, 78 rights remaining after extinguishment / Series 10: 877 rights issued, 850 rights outstanding and unexercised, 720 rights extinguished, 130 rights remaining after extinguishment
Categories and Number of Persons Covered
The Company's directors, employees and external collaborators. Breakdown of the number of people and shares allocated: Not disclosed
Impact on Business Performance
The impact of the extinguishment of these stock acquisition rights on financial results will be immaterial.
| Item | Details |
|---|---|
| Type of issuance or disposal | Extinguishment due to waiver of stock acquisition rights |
| Number of shares to be issued or disposed of | Series 7: 194 rights extinguished (77,600 shares), 78 rights remaining after extinguishment (31,200 shares) / Series 10: 720 rights extinguished (288,000 shares), 130 rights remaining after extinguishment (52,000 shares) |
| Intended allottee | The Company's directors, employees and external collaborators |
| Exercise price | Series 7: ¥814 / Series 10: ¥1,050. Adjustment provision: Not disclosed |
| Exercise period | Series 7: 5 January 2020 to 15 December 2027 / Series 10: 1 October 2019 to 29 September 2029 |
| Number of Stock Acquisition Rights | Series 7: 489 rights issued, 272 rights outstanding and unexercised, 194 rights extinguished, 78 rights remaining after extinguishment / Series 10: 877 rights issued, 850 rights outstanding and unexercised, 720 rights extinguished, 130 rights remaining after extinguishment |
| Categories and Number of Persons Covered | The Company's directors, employees and external collaborators. Breakdown of the number of people and shares allocated: Not disclosed |
| Impact on Business Performance | The impact of the extinguishment of these stock acquisition rights on financial results will be immaterial. |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the share price is substantially below the exercise prices and the anticipated incentive effect cannot be achieved, the Company will waive a portion of the rights based on agreements with the eligible parties, with the aim of issuing new stock acquisition rights suited to the current market environment and share price level.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.